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1Background—We sought to compare the benefit of percutaneous closure to that of medical therapy alone for the secondary 
prevention of embolism in patients with patent foramen ovale (PFO) and otherwise unexplained ischemic stroke, in a 
propensity scored study.
Methods and Results—Between 2000 and 2012, we selected consecutive first-ever ischemic stroke patients aged 18 to 45 years 
with PFO and no other cause of brain ischemia, as part of the IPSYS registry (Italian Project on Stroke in Young Adults), who 
underwent either percutaneous PFO closure or medical therapy for comparative analysis. Primary end point was a composite 
of ischemic stroke, transient ischemic attack, or peripheral embolism. Secondary end point was brain ischemia. Five hundred 
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and twenty-one patients qualified for the analysis. The primary end point occurred in 15 patients treated with percutaneous 
PFO closure (7.3%) versus 33 patients medically treated (10.5%; hazard ratio, 0.72; 95% confidence interval, 0.39–1.32; 
P=0.285). The rates of the secondary end point brain ischemia were also similar in the 2 treatment groups (6.3% in the PFO 
closure group versus 10.2% in the medically treated group; hazard ratio, 0.64; 95% confidence interval, 0.33–1.21; P=0.168). 
Closure provided a benefit in patients aged 18 to 36 years (hazard ratio, 0.19; 95% confidence interval, 0.04–0.81; P=0.026) 
and in those with a substantial right-to-left shunt size (hazard ratio, 0.19; 95% confidence interval, 0.05–0.68; P=0.011).
Conclusions—PFO closure seems as effective as medical therapy for secondary prevention of cryptogenic ischemic stroke. 
Whether device treatment might be more effective in selected cases, such as in patients younger than 37 years and in those 
with a substantial right-to-left shunt size, deserves further investigation.  (Circ Cardiovasc Interv. 2016;9:e003470. 
DOI: 10.1161/CIRCINTERVENTIONS.115.003470.)
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WHAT IS KNOWN
•	Whether percutaneous closure of patent foramen 
ovale is an effective treatment option for secondary 
prevention of otherwise unexplained ischemic stroke 
(cryptogenic stroke) is still unclear.
•	Practitioners need additional patient data to better 
define optimal treatment in individual cases.
WHAT THE STUDY ADDS
•	Overall, there is no significant difference between 
percutaneous patent foramen ovale closure and med-
ical therapy for secondary prevention of cryptogenic 
ischemic stroke.
•	Percutaneous closure might be more effective in pa-
tients younger than 37 years and in those with a sub-
stantial right-to-left shunt size.
•	Subgroups of patients can be identified in whom de-
vice closure is superior to medical therapy.
Up to 61% of cryptogenic stroke patients younger than 55 years of age have patent foramen ovale (PFO), a cardiac 
interatrial septal abnormality residual of the fetal circulation. 
Evidence from observational studies suggests an association 
between cryptogenic stroke and PFO1–5 and a 3-fold increased 
risk of recurrent stroke in PFO carriers.6 Therefore, it has been 
postulated that PFO closure would result in a decreased risk of 
recurrent neurological events (transient ischemic attack [TIA], 
stroke, or death because of stroke) through the elimination of 
the conduit for paradoxical embolism. In spite of this epide-
miological evidence, results from 3 recently published ran-
domized controlled trials (RCTs) failed to show a significant 
benefit of transcatheter PFO closure compared with medical 
therapy.7–9 The 3 trials, however, share several limitations, 
the most relevant of which were the recruitment rate lower 
than expected, probably because of off-label closure, the high 
loss to follow-up, and the small number of recurrent events, 
raising the possibility of an underpowered comparison. In the 
absence of definitive results from clinical trials, the precise 
definition of which patients should be considered for PFO clo-
sure is still unclear. Of note, one of the many subgroup anal-
yses of the CLOSURE I trial (Evaluation of the STARFlex 
Closure System in Patients with a Stroke and/or Transient 
Ischemic Attack due to Presumed Paradoxical Embolism 
through a Patent Foramen Ovale) suggested benefit for device 
in patients under the age of 40 years.10 Similarly, PFO clo-
sure with Amplatzer device was associated with a decrease in 
recurrent, nonfatal ischemic stroke (IS), whereas no benefit 
was observed in the study using the STARFlex device.11 The 
effectiveness of percutaneous closure of PFO was also greater 
in patients with a substantial shunt size according to a further 
stratified analysis.12 These findings implicate that, perhaps, 
subgroups of patients can be identified in whom device clo-
sure is safe and superior to medical therapy and that additional 
patient data are needed to better define optimal treatment in 
individual cases. To further investigate these issues, we tested 
the effectiveness of percutaneous PFO closure compared with 
medical treatment in the setting of the IPSYS registry (Italian 
Project on Stroke in Young Adults).
Methods
Patients and Study Design
IPSYS is a countrywide network of neurological centers with spe-
cial interest in cerebral ischemia at young age across Italy, aimed at 
recruiting white patients with first-ever acute stroke who fulfill the 
following criteria: (1) age 18 to 45 years, (2) computed tomogra-
phy– or magnetic resonance imaging–proven cerebral infarction, in 
the setting of a hospital-based, multicenter, observational study. The 
study was approved by the local Ethics Committee. Informed con-
sent was provided by all study participants. Structure and methods of 
the IPSYS project have been described in detail previously.13 For the 
purpose of the present analysis, we screened data sets from patients 
consecutively admitted to 22 hospitals. The recruitment period was 
January 2000 through January 2012, and follow-up was completed at 
January 2013.14 All patients underwent an extensive etiologic work-
up aimed at determining the most likely mechanism of stroke in each 
case (e-Methods for risk factor definition and diagnostic work-up). 
Patients were categorized according to an etiologic classification 
based on the Trial of Org 10172 in Acute Stroke Treatment criteria, 
accommodated and validated for stroke in the young.15 Only those 
patients whose cerebral infarct (1) was presumably related to PFO 
in the presence of cardiac interatrial right-to-left shunt (RLS) and (2) 
did not meet the criteria for other etiologic categories were included 
in the present analysis.
Assessment of PFO
Interatrial RLS was assessed in all patients with transesophageal 
echocardiography with a contrast study and Valsalva maneuver (c-
TEE) or transcranial Doppler sonography with intravenous injection 
of agitated saline (c-TCD). A RLS was considered present if any 
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microbubble was seen in the left atrium within 3 cardiac cycles from 
maximum right atrial opacification on echocardiography.5 c-TCD was 
performed according to the Venice Consensus Conference.16 Briefly, it 
consists of the injection of 9 mL of saline solution and 1 mL air mixed 
with a 3-way stopcock by exchange of saline/air mixture between 
the syringes and injected as a bolus as a contrast-enhancing agent 
into the right cubital vein 5 seconds before the start of a 10-second 
Valsalva maneuver, while recording the flow velocity of the middle 
cerebral artery, insonated through the temporal window on the right 
side at a depth of 50 to 60 mm, with a handheld probe. The appear-
ance of transient spikes on the velocity spectral curve is considered 
positive for interatrial RLS. The method has an overall diagnostic 
accuracy comparable to that of c-TEE.17 The shunt on c-TCD was 
graded according to a previously described classification: small (<10 
microembolic signals, MES) and moderate to large (>10 microem-
bolic signals, and, in particular, shower pattern if >25 microembolic 
signals and curtain pattern if uncountable microembolic signal). On 
c-TEE, the shunt was graded as small if <10 bubbles passed only after 
Valsalva maneuver, moderate if 10 to 20 bubbles passed only after 
Valsalva maneuver, and large if there was intense opacification of the 
left atrium after Valsalva maneuver (>20 bubbles) or if there was any 
passage at rest.18–20 We defined substantial shunts as those shunts that 
were other than small on c-TCD or c-TEE.
Treatment
The decision in favor of medical therapy rather than treatment with 
percutaneous catheter-based closure of PFO was at the discretion of 
the treating physician and the individual preference of the patient. 
Antithrombotic therapy in the medical treatment group was also left 
to the discretion of the physician in charge with the patient and in-
cluded antiplatelet agents (acetylsalyclic acid at the dose of 100–325 
mg or clopidogrel at the dose of 75 mg once daily) or oral anticoagu-
lation with warfarin (with a target international normalized ratio of 
2.0–3.0). Other treatments for secondary prevention were adminis-
tered in accordance with published guidelines.21 Percutaneous PFO 
closure was achieved under local anesthesia and fluoroscopic guid-
ance using standardized techniques in all the centers. The choice of 
the device and its size was left to the preference of the performing 
physician, based on atrial septal anatomy and patient size. A trans-
thoracic echocardiography was conducted within 24 hours after the 
procedure to document correct device position, and a c-TEE or a c-
TCD was performed after 6 months to search for a residual shunt. 
Antithrombotic treatment in these patients included acetylsalicylic 
acid at a dose of 100 to 325 mg once daily for 6 months and ticlopi-
dine at a dose of 250 mg twice daily or clopidogrel at a dose of 75 mg 
daily for 1 to 6 months.
Outcomes
Only patients who survived the index event were entered into the 
present analysis. Death was considered because of the index stroke if 
it occurred within 30 days of symptoms onset. Subjects were included 
in the subgroup of patients who did not experience recurrence if they 
had at least a 1-year follow-up. Follow-up evaluations were conduct-
ed at 3 months and then annually, and outcome events classified using 
information from interviews (directly during follow-up visits or by 
telephone) with patients, next of kin, witnesses, and attending physi-
cians or from hospital or general practitioner records.
Long-term vascular recurrence was defined as any event of fatal 
or nonfatal IS, TIA, or fatal/nonfatal peripheral embolism. Recurrent 
IS was defined using the same criteria applied for the definition of 
the index event. Diagnosis of TIA was made when the patient had 
reliably observed transient (<24 hours) neurological deficit of abrupt 
onset, without evidence of an underlying nonvascular cause, accord-
ing to the consulting neurologist or the attending physician who 
evaluated the event by clinical and imaging methods.22 Deaths were 
classified using death certificates, medical records, and family inter-
views. In those cases in which it was difficult to make a precise deter-
mination of the cause of death, consensus was reached based on the 
best available information. If more than one recurrent event occurred, 
the first was used for calculation of the disease-free survival time. 
Primary end point was a composite of IS, TIA, or peripheral arterial 
embolism. Secondary end points were (1) brain ischemia (IS or TIA) 
and (2) peripheral embolism.
Statistical Analyses
Duration of follow-up was calculated in person-months by using the 
follow-up of each participant from baseline examination until recur-
rent event or most recent, censored, follow-up assessment.
Descriptive group comparisons were performed using χ2 test for 
categorical variables and t test for continuous variables. Long-term 
outcomes were examined by using propensity score (PS) methods.23 
The PS is the probability that a patient would have been treated with 
PFO closure given his pretreatment variables. Equal PS values guar-
antee equal distribution of measured pretreatment variables at base-
line on the sample level; thus, PS is an attempt to create homogeneous 
groups for comparison when data from a randomization procedure 
are not available. The individual propensity scores for analyzing 
PFO closure and medical therapy groups were estimated with a logit 
model with age, sex, and pretreatment variables that differed between 
groups in a univariate analysis at 2-side P value <0.1. To estimate 
treatment effects, Cox proportional hazards models were performed 
on the entire cohort to derive crude, PS-adjusted, and PS-weighted 
HRs. PS-adjusted HRs were obtained including in the Cox model the 
PS scores as a covariate with cubic spline functions.24 PS-weighted 
HRs used inverse probability of treatment weights in all patients, with 
the inverse PS as weight for patients receiving PFO closure and the 
inverse of 1 minus the PS as weight for patients with medical thera-
py.25 The analysis of the primary composite end point was performed 
overall and stratified by 2 strata according to median age (18–36 years 
versus 37–45 years), sex (men versus women), shunt size (substan-
tial shunt versus other size), medical treatment (anticoagulant versus 
antiplatelet), and device type (Amplatzer versus others). All P values 
and 95% confidence intervals were 2 sided. Analyses were performed 
with R packages (release 3.1.2).26
Results
Of the 1906 patients included in the IPSYS registry, 39 (2.0%) 
were lost during follow-up. Five hundred and twenty-one 
patients with PFO and no other potential cause of brain isch-
emia were entered into the present analysis (Figure 1).
Of these, 315 (60.5%) were treated medically and 206 
(39.5%) underwent percutaneous closure. The follow-
ing devices for percutaneous closure were used: Amplazer 
Occluders (AGA Medical Corporation, Golden Valley, MN; 
86.8%), CardioSEAL (NMT Medical, Boston, MA; 1.9%), 
STARFlex (NMT Medical, Boston, MA; 2.4%), GORE 
HELEX Septal Occluder (Gore Medical, Flagstaff, AZ; 
2.4%), BioSTAR (NMT Medical, ; 1.9%), Premere (St. Jude 
Medical, Maple Grove, MN; 3.3%), Figulla ASD Occluder 
(Occlutech GmbH, Jena, Germany; 0.9%), and ATRIASEPT 
(Cardia Inc, Eagan, MN; 0.4%). The rate of serious adverse 
events did not differ significantly in the 2 groups (Table I 
in the Data Supplement). In particular, new-onset atrial 
fibrillation was detected in 3 patients (1.5%) in the closure 
group and in 1 patient (0.3%) in the medical therapy group 
(P=0.306). None of these patients had subsequent end point 
events. Complete PFO closure was observed in 190 patients 
(92.2%), whereas a small shunt persisted in 16 (7.8%). 
Median follow-up time was 36.0 months (25th to 75th per-
centile, 58.0; 13.5–72.5 months) for the medical treatment 
group versus 32.0 months (25th to 75th percentile, 37.0; 16–
52.25 months) for the PFO closure group. The accumulated 
(mass) person-months were 14 206 in the medical treatment 
group and 8483 in the PFO closure group. The 2 groups were 
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similar with respect to baseline characteristics, except for a 
greater proportion of hypertensive patients among patients 
treated medically and of migraine sufferers among those 
who underwent PFO closure (Table 1).
Antiplatelet drugs were the preferred option for long-
term secondary prevention in patients treated medically 
(259 patients [82.2%] versus 56 [17.8%] who received oral 
anticoagulants).
Table 2 and Figure 2A and 2B summarize primary and 
secondary end points of the comparison between patients who 
received transcatheter PFO closure and those treated medi-
cally. The primary composite end point occurred in 15 patients 
treated with percutaneous PFO closure (7.3%) versus 33 
patients who received medical treatment (10.5%; crude haz-
ard ratio, 0.72; 95% confidence interval, 0.39–1.32; P=0.285). 
The rates of the secondary end point brain ischemia were also 
similar in the 2 treatment groups (6.3% in the PFO closure 
group versus 10.2%; crude hazard ratio 0.64; 95% confidence 
interval, 0.33–1.21; P=0.168). We then computed propensity 
scores by using the variables age, sex, hypertension, diabe-
tes mellitus, migraine, and family history as PS predictors. 
In the entire cohort, adjusted PS and inverse probability of 
treatment–weighted HRs were compatible to crude HRs (95% 
confidence intervals overlapped the null [hazard ratio, 1]) for 
both the primary end point and the secondary composite end 
point brain ischemia (IS or TIA; Table 2).
To determine the potential heterogeneity of the treatment 
effect and identify subpopulations of patients that might ben-
efit most from receiving one therapeutic approach, we per-
formed stratified analyses by splitting patients according to 
baseline covariates. Findings suggested that closure might 
provide a greater benefit in younger patients (aged <37 years) 
and in those with a substantial RLS size (Figure 3).
Discussion
The crucial clinical question on PFO during the past 15 years 
has been whether percutaneous closure is superior to medi-
cal therapy in stroke secondary prevention. Although all of 
the randomized trials reported to date failed to show any 
significant differences between the 2 treatments, they are 
clearly insufficient to draw any conclusion, mainly because 
of methodological drawbacks, including sample size of the 
study cohorts smaller than expected and event rates lower 
than anticipated in the follow-up.27 The other trials currently 
ongoing (Gore REDUCE trial [NCT00738894] and CLOSE 
trial [NCT00562289]) are likely to face the same statistical 
limitations. As a practical implication of this, it seems unlikely 
that the results of RCTs will change the opinion of clinicians 
about the use of an approach over the other. In the absence of 
definitive trial results, therefore, practitioners need more data 
to consider when deciding whether a stroke patient is likely 
to have a high-risk PFO and which treatment option is the 
best in individual cases. The results of our prospective cohort 
study provide information in this regard. Because, overall, we 
were unable to detect any benefit of percutaneous PFO closure 
compared with medical treatment on the primary end point, a 
composite of stroke, TIA, or peripheral embolism, our findings 
reinforce the randomized trials evidence of clinical equipoise 
for the 2 treatments. In contrast, although we cannot exclude 
a priori the possibility of underpowered comparison, we found 
differential effect estimates according to subgroups in strati-
fied analyses. In particular, transcatheter PFO closure seemed 
superior to medical therapy for secondary prevention in stroke 
patients younger than 37 years and in those with a large RLS. 
Of note, these findings are in line with those from specific sub-
group analyses of RCTs. Actually, benefit for device closure 
over medical therapy was observed in patients aged ≤40 years 
in CLOSURE I10 and in those with a substantial RLS size8 and 
aged <60 years in RESPECT28 and in one of the meta-analyses 
of randomized data.12 These 2 characteristics have been also 
associated with an increased likelihood that a stroke is related 
to PFO in epidemiological studies,29 which provides supportive 
evidence to the prevailing idea that there might be subgroups of 
patients in whom device closure is superior to medical therapy.
Because of its characteristic of real-world patient popula-
tion, the IPSYS cohort is reasonably more representative of 
patients with PFO and otherwise unexplained IS than those 
included in controlled studies. Any decision favoring off-
label device closure versus medical therapy is likely to reflect 
clinical practice more closely in this setting, although a for-
mal proof of this generalizability is lacking. On the contrary, 
collecting data on the basis of a predefined clinical protocol 
allowed us to collect baseline and follow-up information using 
Figure 1. Flow chart of patients selection. IPSYS indicates  
Italian Project on Stroke in Young Adults; and PFO, patent  
foramen ovale.
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uniform procedures in all patients, thereby reducing the risk of 
information bias due, for example, to differential intensity and 
thoroughness of follow-up examinations. Because the present 
analysis is just one among those we had planned to perform 
in the setting of the collaborative IPSYS project, any differen-
tial outcome ascertainment in medically treated patients com-
pared with closure-treated patients seems unlikely.
There are also some notable limitations of our study that 
should be considered. First, because of its nonrandomized 
design, we cannot exclude that results are subject to confound-
ing by indication. However, although it is theoretically possible 
that unmeasured characteristics might have differed between 
patients and confounded our results, the application of pro-
pensity score, a robust method of adjustment for confounders 
that minimizes their effects, is a strength of our analysis com-
pared with others based on traditional, less adequate, methods 
of multivariate adjustment.30 This makes our findings reliable. 
To our knowledge, among the comparative observational 
Table 1. Demographic and Clinical Characteristics of the Study Group
Variable
PFO Closure (n=206) Medical Treatment (n=315)
P ValueMean ± SD Mean ± SD
Age, y, mean±SD 35.3±7.4 35.7±6.8 0.525
n (%) n (%)
Men 94 (45.6) 154 (48.9) 0.467
Hypertension 20 (9.7) 52 (16.5) 0.028
Diabetes mellitus 0 (0.0) 5 (1.6) 0.069
Current smokers 64 (31.0) 100 (31.7) 0.833
Hypercholesterolemia 39 (18.9) 67 (21.2) 0.494
History of migraine 0.054
  No migraine 130 (63.1) 230 (73.0)
  MO 43 (20.9) 46 (14.6)
  MA 33 (16.0) 39 (12.4)
Oral contraceptives* 44 (39.3) 47 (29.2) 0.082
Family history of stroke 38 (18.4) 79 (25.0) 0.076
Heavy alcohol consumption 16 (7.8) 21 (6.6) 0.633
FV
G1691A
0.347
  GG 193 (93.7) 301 (95.6)
  AG 13 (6.3) 14 (4.4)
  AA 0 (0.0) 0 (0.0)
PT
G20210A
0.611
  GG 197 (95.6) 304 (96.5)
  AG 9 (4.4) 11 (3.5)
  AA 0 (0.0) 0 (0.0)
FV indicates factor V; MA, migraine with aura; MO, migraine without aura; PFO, patent foramen ovale; and PT, prothrombin.
*In women.
Table 2. Clinical Outcomes in the Overall Cohort
PFO Closure, 
n (%)
Medical 
Treatment, 
n (%)
Crude PS Adjusted IPT Weigthed
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
Primary end point
  IS, TIA, or 
peripheral 
embolism
15/206 (7.3) 33/315 (10.5) 0.72 (0.39–1.32) 0.285 0.69 (0.37–1.31) 0.262 0.68 (0.36–1.29) 0.238
Secondary end point
  IS or TIA 13/206 (6.3) 32/315 (10.2) 0.64 (0.33–1.21) 0.168 0.61 (0.31–1.19) 0.149 0.59 (0.30–1.14) 0.114
CI indicates confidence interval; HR, hazard ratio; IPT, inverse probability of treatment; IS, ischemic stroke; PFO, patent foramen ovale; PS, propensity score; and TIA, 
transient ischemic attack.
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Figure 2. Kaplan–Meier estimates for primary 
end point events (A) and secondary end point 
events (B). PFO indicates patent foramen 
ovale.
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studies published to date, only one single-center, propensity 
score–matched analysis was reported, which showed a ben-
efit of percutaneous PFO closure over medical therapy in TIA 
secondary prevention.31 The long-term follow-up duration of 
that study as compared with other studies including ours is a 
major strength of the analysis and provides reliable informa-
tion on the long-term effectiveness and safety of percutaneous 
PFO closure. Nonetheless, the mean duration of follow-up in 
our analysis is in line with that of the 3 comparative RCTs 
on PFO closure. Our observation that covariates were in good 
balance in 2 treatment groups even before PS matching is a 
further argument against the possibility that a substantial 
selection bias might have occurred. Second, our study has a 
long inclusion period, during which acute treatment and sec-
ondary prevention and devices and techniques for PFO clo-
sure have improved. Closure devices have changed over time, 
and different attitudes across centers might theoretically have 
had an impact on the results as well.12 This is an unavoidable 
feature of a multicenter, long-term, longitudinal study with 
a stringent age cutoff for patient inclusion like ours, whose 
potential implications are noteworthy. However, although we 
were unable to perform separate subgroup analyses for each 
device category because of the low number of patients, we 
did not detect outcome differences according to the type of 
device used. Third, patients underwent PFO closure at differ-
ent time points after the index event, which might represent a 
further potential drawback. However, as in the device closure 
arm, we considered person-time after the procedure for the 
analysis, it seems unlikely that this has significantly altered 
the results of our study. Fourth, the TCD technique we used 
for the diagnosis of interatrial RLS in some cases prevents the 
assessment of atrial septal aneurysm, which does not allow to 
achieve precise data on the frequency of atrial septal aneurysm 
in our series and to perform subgroup analyses on different 
cohort strata defined by atrial septal aneurysm. Fifth, TIA is 
a less clear-cut end point than stroke and has several mimick-
ing conditions, particularly in younger individuals. However, 
at least biologically, TIAs represent reliable markers of failed 
secondary prevention just as major strokes or any other throm-
botic events and, as such, they should not be excluded from 
long-term comparative analyses. Finally, estimates for some 
subgroups that contain only a few patients might be unstable 
and should, therefore, be interpreted with caution. Although 
the implications of these potential shortcomings should be 
taken into account, it seems unlikely that they have signifi-
cantly altered the results of our study.
In conclusion, although the true efficacy of PFO closure in 
patients with otherwise unexplained ischemic stroke remains 
to be definitively assessed, the results of the present analysis 
conducted in patients between 18 and 45 years of age support 
the evidence from RCTs that this approach provides no signifi-
cant benefit over medical therapy alone. Whether device treat-
ment might be more effective for secondary stroke prevention 
in appropriately selected cases, with acceptably low periproce-
dural complication rates, such as younger patients and patients 
with a substantial RLS size deserves further investigation.
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